Medical cannabis company AusCann Group Holdings (ASX:AC8)
has bought a research and development facility in Perth in WA.
The facility will focus on AusCann’s cannabinoid pharmaceutical product pipeline, supporting development of both innovative formulations and dose forms.
AusCann Executive Director and interim CEO Dr Paul MacLeman says it allows the creation of a fully integrated, state of the art facility for medicinal cannabis.
Shares in AusCann Group Holdings (ASX:AC8)
are trading 1.57 per cent higher at $0.65.